+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis



Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis



Antimicrobial Agents and ChemoTherapy 50(7): 2464-2470



The in vitro susceptibilities of Cryptococcus neoformans isolates from consecutive human immunodeficiency virus-positive and -negative patients to the antifungal agents fluconazole, amphotericin B, and flucytosine were determined by different techniques, including the CLSI method, Etest, and broth microdilution in yeast nitrogen base (YNB) medium, during a multicenter prospective study in France. The relationship between the in vitro data and the clinical outcome 2 weeks after the initiation of antifungal therapy was assessed. In addition, the correlation between the strain serotype and the in vitro activities of the antifungals was determined, and the susceptibility results obtained with the different techniques were also compared. Thirty-seven patients received a combination of amphotericin B with flucytosine as first-line therapy, 22 were treated with amphotericin B alone, and 15 received fluconazole alone. Whatever the antifungal tested, there was no trend toward higher MICs for strains isolated from patients who failed to respond to a given therapy compared to those from patients who did not with either the CLSI method, Etest, or broth microdilution in YNB medium. The MICs obtained by the CLSI or Etest method were significantly lower for serotype D strains than for serotype A strains for both fluconazole and amphotericin B, while flucytosine MICs were not different according to serotype. These findings suggest that the in vitro antifungal susceptibility of C. neoformans, as determined with the techniques used, is not able to predict the early clinical outcome in patients with cryptococcosis.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012816895

Download citation: RISBibTeXText

PMID: 16801427

DOI: 10.1128/aac.01520-05


Related references

Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. Journal of Antimicrobial ChemoTherapy 66(11): 2581-2584, 2011

In vitro susceptibility of cryptococcus neoformans to antifungal drugs relationship with clinical outcome of cryptococcosis. Viii International Conference on Aids And The Iii Std World Congress Viii International Conference on Aids And The Iii Std World Congress; Harvard-Amsterdam Conference, Amsterdam, Netherlands, July 19-24, Pagination Varies Viii International Conference on Aids And The Iii Std World Congress: Amsterdam, Netherlands Paper : b124, 1992

Antifungal susceptibility testing on isolates of Histoplasma capsulatum obtained from a clinical trial evaluating fluconazole treatment in patients with AIDS. Abstracts of the General Meeting of the American Society for Microbiology 96: 85, 1996

Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical Microbiology and Infection 13(10): 1018-1022, 2007

Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole. Infection 22(2): 132-136, 1994

Comparison of the Vitek 2 antifungal susceptibility system with the clinical and laboratory standards institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) Broth Microdilution Reference Methods and with the Sensititre YeastOne and Etest techniques for in vitro detection of antifungal resistance in yeast isolates. Journal of Clinical Microbiology 48(5): 1782-1786, 2010

Correlation between in vitro susceptibility to antifungal drugs and the clinical evolution of patients with candidiasis and cryptococcosis. Revista Espanola de Quimioterapia 15(1): 32-42, 2002

Correlation of antifungal susceptibility testing with clinical outcome. Clinical Infectious Diseases 25(2): 382, 1997

Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clinical Microbiology and Infection 9(6): 467-474, 2003

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clinical Infectious Diseases 24(2): 235-247, 1997

Antifungal susceptibility testing and the correlation with clinical outcome in neonatal candidemia. American Journal of Perinatology 18(3): 141-146, 2001

Comparison of three antifungal susceptibility testing methods for the in vitro testing of Candida isolates from patients with HIV infection. Mycoses 39(Suppl. 2): 47-50, 1996

Comparison of susceptibility testing results obtained for Candida tropicalis isolates with decreased azole-susceptibility by disc diffusion and agar dilution methods. 2008

Comparison of Vitek identification and antifungal susceptibility testing methods to DNA sequencing and Sensititre YeastOne antifungal testing. Medical Mycology 49(1): 107-110, 2011